ED90 of Bupivacaine After Lidocaine Test Dose with DPE and EPL

Last updated: February 6, 2025
Sponsor: Brigham and Women's Hospital
Overall Status: Active - Recruiting

Phase

4

Condition

Acute Pain

Treatment

Bupivacaine Hydrochloride

Clinical Study ID

NCT06146842
2023p003001
  • Female
  • Accepts Healthy Volunteers

Study Summary

The primary objective of our study is to use a biased coin up-down allocation methodology to estimate the dose of bupivacaine required after the lidocaine test dose to achieve initial effective comfort in 90% of patients (post test-dose ED90) via the epidural (DPE or EPL) technique in women undergoing labor induction or augmentation; the investigators hypothesize that the investigators will be able to determine the post test-dose ED90 of bupivacaine for each technique with adequate precision to inform the optimal doses to study in a subsequent randomized trial comparing the analgesic effects of DPE vs. EPL. The investigators also hypothesize that the post test-dose ED90 of bupivacaine is lower with a DPE technique than with a conventional epidural technique.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Parturient with no major co-morbidities

  2. Singleton, vertex gestation at term (37-42 weeks)

  3. Less than or equal to 5 cm dilation

  4. Desire to receive epidural labor analgesia

  5. Numerical Rating Scale greater than or equal to 5 (NRS 0-10, where 0 = no pain, and 10 = worst pain imaginable), at time of epidural labor analgesia request.

Exclusion

Exclusion Criteria:

  1. Current or historical evidence of clinically significant disease or condition,including diseases of pregnancy (i.e., preeclampsia, gestational diabetes)

  2. Any contraindication to the administration of an epidural technique (e.g.,thrombocytopenia, antiplatelet meds).

  3. History of hypersensitivity or idiosyncratic reaction to an amide local anestheticagent

  4. Evidence of anticipated fetal complications (i.e., fetal anomalies, IUGR (Intrauterine Growth Restriction), oligohydramnios, polyhydramnios)

Study Design

Total Participants: 120
Treatment Group(s): 1
Primary Treatment: Bupivacaine Hydrochloride
Phase: 4
Study Start date:
December 01, 2023
Estimated Completion Date:
January 31, 2026

Study Description

The investigators will be conducting a randomized controlled trial with patients randomized into either an EPL or a DPE group. For the first subject in the DPE and EPL techniques, the initial dose of bupivacaine 25 mg will be used, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments. Hence, if the first subject does not respond successfully, the dose for the second subject will be bupivacaine 27.5 mg. If the second subject does not respond successfully, the dose for the third subject will be bupivacaine 30 mg. By contrast, if a subject responds successfully, the bupivacaine dose will be decreased to 22.5 mg with a probability of 10% and maintained with a probability of 90% (ratio 1:9).

Connect with a study center

  • Brigham and Women's Hospital

    Boston, Massachusetts 02115
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.